Drug Profile
IQP 0528
Alternative Names: DuoGel; IQP-0528Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Samjin Pharmaceutical Company
- Developer ImQuest Life Sciences; John Hopkins University; National Institute of Allergy and Infectious Diseases
- Class Antivirals; Pyrimidinones; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in HIV-infections(Prevention) in USA (Rectal, Gel)
- 20 Jul 2020 ImQuest Life Sciences has been acquired by Cytocom
- 02 Jun 2019 Johns Hopkins University ImQuest Pharmaceuticals National Institute of Allergy and Infectious Diseases completes a phase I trial for HIV infections (Prevention) in USA (Rectal) (NCT03082690)